Literature DB >> 12566519

Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas.

L Kluwe1, V Mautner, B Heinrich, R Dezube, L B Jacoby, R E Friedrich, M MacCollin.   

Abstract

Neurofibromatosis 2 (NF2) is a severe autosomal dominant disorder that predisposes to multiple tumours of the nervous system. About half of all patients are founders with clinically unaffected parents. The purpose of the present study was to examine the extent to which mosaicism is present in NF2 founders. A total of 233 NF2 founders with bilateral vestibular schwannomas (BVS) were screened by exon scanning. NF2 mutations were detected in the blood samples of 122 patients (52%). In 10 of the 122 cases, the ratio of mutant to normal alleles was obviously less than 1, suggesting mosaicism. Tumour specimens were available from 35 of the 111 subjects in whom no mutation could be detected in blood specimens. Mutational analysis by exon scanning detected typical NF2 mutations in 21 of the 35 tumours. In nine subjects, the alterations found in tumours could be confirmed to be the constitutional mutation based on finding of identical mutations in pathologically and/or anatomically distinct second tumours. In six other subjects with only a single tumour available, allelic loss of the NF2 gene was found in addition to the mutation in each tumour, suggesting that either the mutation or the deletion of the NF2 gene is probably the constitutional genetic alteration. Our results suggest that failure to find constitutional mutations in blood specimen from these 15 patients was not because of the limitation of the applied screening technique, but the lack of the mutations in their leucocytes, best explained by mosaicism. Extrapolating the rate (15/35 = 43%) of mosaicism in these 35 cases to the 111 NF2 founders with no constitutional NF2 mutations found in their blood, we inferred 48 mosaic subjects (111 x 0.429). Adding the 10 mosaic cases detected directly in blood specimens, we estimate the rate of mosaicism to be 24.8% (58/233) in our cohort of 233 NF2 founders with bilateral vestibular schwannomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12566519      PMCID: PMC1735360          DOI: 10.1136/jmg.40.2.109

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  27 in total

Review 1.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

Authors:  D H Gutmann; A Aylsworth; J C Carey; B Korf; J Marks; R E Pyeritz; A Rubenstein; D Viskochil
Journal:  JAMA       Date:  1997-07-02       Impact factor: 56.272

2.  Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes.

Authors:  L Kluwe; S Bayer; M E Baser; W Hazim; W Haase; C Fünsterer; V F Mautner
Journal:  Hum Genet       Date:  1996-11       Impact factor: 4.132

3.  Frequency and distribution of NF2 mutations in schwannomas.

Authors:  L B Jacoby; M MacCollin; R Barone; V Ramesh; J F Gusella
Journal:  Genes Chromosomes Cancer       Date:  1996-09       Impact factor: 5.006

4.  Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis.

Authors:  L B Jacoby; D Jones; K Davis; D Kronn; M P Short; J Gusella; M MacCollin
Journal:  Am J Hum Genet       Date:  1997-12       Impact factor: 11.025

5.  Misleading linkage results in an NF2 presymptomatic test owing to mosaicism.

Authors:  E K Bijlsma; A J Wallace; D G Evans
Journal:  J Med Genet       Date:  1997-11       Impact factor: 6.318

6.  Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis.

Authors:  D G Evans; A J Wallace; C L Wu; L Trueman; R T Ramsden; T Strachan
Journal:  Am J Hum Genet       Date:  1998-09       Impact factor: 11.025

7.  Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.

Authors:  D G Evans; L Trueman; A Wallace; S Collins; T Strachan
Journal:  J Med Genet       Date:  1998-06       Impact factor: 6.318

Review 8.  A point mutation associated with a severe phenotype of neurofibromatosis 2.

Authors:  M MacCollin; N Braverman; D Viskochil; M Ruttledge; K Davis; R Ojemann; J Gusella; D M Parry
Journal:  Ann Neurol       Date:  1996-09       Impact factor: 10.422

9.  NF2 gene in neurofibromatosis type 2 patients.

Authors:  J Zucman-Rossi; P Legoix; H Der Sarkissian; G Cheret; F Sor; A Bernardi; L Cazes; S Giraud; E Ollagnon; G Lenoir; G Thomas
Journal:  Hum Mol Genet       Date:  1998-12       Impact factor: 6.150

10.  Mosaicism in sporadic neurofibromatosis 2 patients.

Authors:  L Kluwe; V F Mautner
Journal:  Hum Mol Genet       Date:  1998-12       Impact factor: 6.150

View more
  32 in total

1.  Glioblastoma multiforme presenting as bilateral internal auditory canal tumors.

Authors:  J W Lee; M Houtchens; F Hochberg; B Price; Lev M; M Cunnane; R Pfannl; M MacCollin
Journal:  J Neurol       Date:  2006-03-20       Impact factor: 4.849

2.  Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.

Authors:  Camille Louvrier; Eric Pasmant; Audrey Briand-Suleau; Joëlle Cohen; Patrick Nitschké; Juliette Nectoux; Lucie Orhant; Cécile Zordan; Cyril Goizet; Stéphane Goutagny; Dominique Lallemand; Michel Vidaud; Dominique Vidaud; Michel Kalamarides; Béatrice Parfait
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

3.  The origin of EFNB1 mutations in craniofrontonasal syndrome: frequent somatic mosaicism and explanation of the paucity of carrier males.

Authors:  Stephen R F Twigg; Kazuya Matsumoto; Alexa M J Kidd; Anne Goriely; Indira B Taylor; Richard B Fisher; A Jeannette M Hoogeboom; Irene M J Mathijssen; M Teresa Lourenco; Jenny E V Morton; Elizabeth Sweeney; Louise C Wilson; Han G Brunner; John B Mulliken; Steven A Wall; Andrew O M Wilkie
Journal:  Am J Hum Genet       Date:  2006-04-28       Impact factor: 11.025

Review 4.  The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.

Authors:  M E Baser; L Kuramoto; R Woods; H Joe; J M Friedman; A J Wallace; R T Ramsden; S Olschwang; E Bijlsma; M Kalamarides; L Papi; R Kato; J Carroll; C Lázaro; F Joncourt; D M Parry; G A Rouleau; D G R Evans
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

Review 5.  News on the genetics, epidemiology, medical care and translational research of Schwannomas.

Authors:  C O Hanemann; D G Evans
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

Review 6.  Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes.

Authors:  Fausto J Rodriguez; Constantine A Stratakis; D Gareth Evans
Journal:  Acta Neuropathol       Date:  2011-12-31       Impact factor: 17.088

7.  Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome.

Authors:  Erin E Salo-Mullen; Jinru Shia; Isaac Brownell; Peter Allen; Monica Girotra; Mark E Robson; Kenneth Offit; Jose G Guillem; Arnold J Markowitz; Zsofia K Stadler
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

8.  Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2.

Authors:  Mikołaj Łaniewski-Wołłk; Monika Gos; Andrzej Koziarski; Agnieszka Szpecht-Potocka
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

9.  Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study.

Authors:  Michael E Baser; Lisa Kuramoto; Harry Joe; J M Friedman; Andrew J Wallace; James E Gillespie; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2004-06-09       Impact factor: 11.025

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.